{
    "title": "114_hr3952",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Congenital Heart Futures \nReauthorization Act of 2015''.\n\nSEC. 2. NATIONAL CONGENITAL HEART DISEASE SURVEILLANCE SYSTEM.\n\n    Section 399V-2 of the Public Health Service Act (42 U.S.C. 280g-13) \nis amended to read as follows:\n\n``SEC. 399V-2. NATIONAL CONGENITAL HEART DISEASE RESEARCH, \n              SURVEILLANCE, AND AWARENESS.\n\n    ``(a) In General.--The Secretary, acting through the Director of \nthe Centers for Disease Control and Prevention, shall--\n            ``(1) enhance and expand research and surveillance \n        infrastructure to study and track the epidemiology of \n        congenital heart disease (in this section referred to as \n        `CHD');\n            ``(2) plan and implement a public outreach and education \n        campaign regarding CHD across the lifespan; and\n            ``(3) award grants to eligible entities to undertake the \n        activities described in subsections (b) and (c).\n    ``(b) National Congenital Heart Disease Cohort Study.--\n            ``(1) In general.--The Director of the Centers for Disease \n        Control and Prevention shall plan, develop, implement, and \n        submit one or more reports to the Congress on a cohort study to \n        improve understanding of the epidemiology of CHD across the \n        lifespan, from birth to adulthood, with particular interest in \n        the following:\n                    ``(A) Health care utilization and natural history \n                of those affected by CHD.\n                    ``(B) Demographic factors associated with CHD, such \n                as age, race, ethnicity, gender, and family history of \n                individuals who are diagnosed with the disease.\n                    ``(C) Outcome measures, such that analysis of the \n                outcome measures will allow derivation of evidence-\n                based best practices and guidelines for CHD patients.\n            ``(2) Permissible considerations.--The study under this \n        subsection may--\n                    ``(A) gather data on the health outcomes of a \n                diverse population of those affected by CHD;\n                    ``(B) consider health disparities among those \n                affected by CHD which may include the consideration of \n                prenatal exposures; and\n                    ``(C) incorporate behavioral, emotional, and \n                educational outcomes of those affected by CHD.\n            ``(3) Public access.--Subject to paragraph (4), the data \n        generated from the study under this subsection shall be made \n        available to the public, including CHD researchers.\n            ``(4) Patient privacy.--The Secretary shall ensure that the \n        study under this subsection is carried out in a manner that \n        complies with the requirements applicable to a covered entity \n        under the regulations promulgated pursuant to section 264(c) of \n        the Health Insurance Portability and Accountability Act of \n        1996.\n    ``(c) Congenital Heart Disease Awareness Campaign.--\n            ``(1) In general.--The Director of the Centers for Disease \n        Control and Prevention shall establish and implement an \n        awareness, outreach, and education campaign regarding CHD \n        across the lifespan. The information expressed through such \n        campaign shall--\n                    ``(A) emphasize that CHD is the most prevalent \n                birth defect;\n                    ``(B) identify CHD as a condition that affects \n                those diagnosed throughout their lives; and\n                    ``(C) promote the need for pediatric, adolescent, \n                and adult individuals with CHD to seek and maintain \n                lifelong, specialized care.\n            ``(2) Permissible activities.--The campaign under this \n        subsection may--\n                    ``(A) utilize collaborations or partnerships with \n                other agencies, health care professionals, and patient \n                advocacy organizations that specialize in the needs of \n                individuals with CHD; and\n                    ``(B) include the use of print, film, and \n                electronic materials distributed via television, radio, \n                Internet, and other commercial marketing venues.\n    ``(d) Eligibility for Grants.--To be eligible to receive a grant \nunder subsection (a)(3), an entity shall--\n            ``(1) be a public or private nonprofit entity with \n        specialized experience in CHD; and\n            ``(2) submit to the Secretary an application at such time, \n        in such manner, and containing such information as the \n        Secretary may require.\n    ``(e) Authorization of Appropriations.--To carry out this section, \nthere is authorized to be appropriated $4,000,000 for each of fiscal \nyears 2016 through 2020.''.\n\nSEC. 3. CONGENITAL HEART DISEASE RESEARCH.\n\n    Section 425 of the Public Health Service Act (42 U.S.C. 285b-8) is \namended to read as follows:\n\n``SEC. 425. CONGENITAL HEART DISEASE.\n\n    ``(a) In General.--The Director of the Institute may expand, \nintensify, and coordinate research and related activities of the \nInstitute with respect to congenital heart disease, which may include \ncongenital heart disease research with respect to--\n            ``(1) causation of congenital heart disease, including \n        genetic causes;\n            ``(2) long-term outcomes in individuals with congenital \n        heart disease, including infants, children, teenagers, adults, \n        and elderly individuals;\n            ``(3) diagnosis, treatment, and prevention;\n            ``(4) studies using longitudinal data and retrospective \n        analysis to identify effective treatments and outcomes for \n        individuals with congenital heart disease; and\n            ``(5) identifying barriers to lifelong care for individuals \n        with congenital heart disease.\n    ``(b) Coordination of Research Activities.--The Director of the \nInstitute may coordinate research efforts related to congenital heart \ndisease among multiple research institutions and may develop research \nnetworks.\n    ``(c) Minority and Medically Underserved Communities.--In carrying \nout the activities described in this section, the Director of the \nInstitute shall consider the application of such research and other \nactivities to minority and medically underserved communities.\n    ``(d) Report From NIH.--Not later than 1 year after the date of \nenactment of the Congenital Heart Futures Reauthorization Act of 2015, \nthe Director of NIH, acting through the Director of the Institute, \nshall provide a report to Congress--\n            ``(1) outlining the ongoing research efforts of the \n        National Institutes of Health regarding congenital heart \n        disease; and\n            ``(2) identifying--\n                    ``(A) future plans for research regarding \n                congenital heart disease; and\n                    ``(B) the areas of greatest need for such \n                research.''."
}